TNFRSF9 and neoplasm: Prospectively banked paired baseline and on-treatment tumor biospecimens collected from the patients in these two arms (Cy-GVAX ± Nivolumab) demonstrated that an increase in the CD137+ activated T-cell subset in TLAs correlated with cytotoxic effector T cell signatures and was associated with improved 2-yr OS9.